Skip to content

Palliative Care in Patients With COVID-19: Analysis of Costs of Hospitalization in Wards and Intensive Care Units

Palliative Care in Patients With COVID-19: Analysis of Costs of Hospitalization in Wards and Intensive Care Units

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05897229
Enrollment
200
Registered
2023-06-09
Start date
2023-10-01
Completion date
2026-10-01
Last updated
2023-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Palliative Care

Keywords

Palliative care, COVID-19, Cost allocation, Cost control, Organization and Administration

Brief summary

The confrontation of COVID-19 foreshadowed a serious crisis of scarce health resources worldwide. To assist in this confrontation, the Palliative Care Scientific Technical Core of the Clinical Hospital, School of Medicine, Sao Paulo University (USP) elaborated a Triage Protocol for Palliative Care (PALI-COVID Tool) and it was possible to categorize the patients in three groups, according to the risk of death and needs of Palliative Care (PC), through the clinical evaluation of the patient that also directed them to the hospitalization resource according to their need (ward x ICU).

Detailed description

The patients grouped as with higher risk of death and PC needs (green group) by PALI-COVID Tool were those with a profile of end-of-life, signs of clinical deterioration and risk of death on admission and thus indicated for admission to the COVID-19 Palliative Care Inpatient Unit, however some were admitted to the ICU. Objective: to analyze the direct costs of hospitalization of COVID-19 Palliative Care patients in Palliative Care Inpatient Unit and ICU screened as green group by the COVID-19 Screening Protocol developed in the institution. Methods: observational, cross-sectional and retrospective study of the service database of patients over 18 years of age screened as the green group (PALI-COVID). The variables to be investigated are related to sociodemographic and clinical data, length of stay and hospitalization scenarios, time to call for PC, outcome and costs.

Interventions

OTHERAnalysis of costs with patient care during hospitalization

Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* inpatients with severe forms of COVID-19 between April 08 and July 31, 2020 * positive reverse-transcriptase polymerase chain reaction (RT-PCR). * patients with terminal illness and high clinical risk of death before COVID-19. * those admitted to an ICU or palliative care unit.

Exclusion criteria

* absence of hospitalization cost data in the institution's electronic records

Design outcomes

Primary

MeasureTime frameDescription
Direct costs (supplies)Hospitalizations between April 8th to July 31th, 2020costs related to supplies, medications, diets, laboratory tests, imaging exams, and invasive procedures (such as mechanical ventilation, dialysis, and the use of vasoactive drugs). The costs will be calculate for the three groups and compared between them.
Direct costs (working hours)Hospitalizations between April 8th to July 31th, 2020costs referring to working hours of health professionals (physicians, nurses and physical therapists) in each unit normalized for the same number of beds. The costs will be calculate for the three groups and compared between them.
Cost minimization, and consequential cost analysisHospitalizations between April 8th to July 31th, 2020all the costs will be compared between them to do a cost-effectiveness analysis as the death rate will be probabily similar in the three groups.

Secondary

MeasureTime frameDescription
Time to call Palliative Care groupHospitalizations between April 8th to July 31th, 2020admission to the institution, date of call of PC, first assessment of PC, indication of transfer to a COVID-19 PC unit, and date of transfer to PC unit to identify and analyze the time it took for staff to recognize the need for CP for the patients that has repercussions on the cost of hospitalization.
Life-sustaining proceduresHospitalizations between April 8th to July 31th, 2020such as mechanical ventilation, dialysis, and the use of vasoactive drugs to identify and analyze the use of life-sustaining procedures in the study population and analyze the costs.
Sociodemographic profileHospitalizations between April 8th to July 31th, 2020age and sex to identify and analyze the profile of the patients included in the study.
Outcome of hospitalizationHospitalizations between April 8th to July 31th, 2020hospital discharge, transference, and death to identify and analyze the profile of the patients included in the study and to make a cost-effectiveness analysis with the all costs that will be analyzed.
Inpatient daily ratesHospitalizations between April 8th to July 31th, 2020rates for Palliative Care unit (PC), ICU and PC & ICU to analyze the costs.
Clinical profileHospitalizations between April 8th to July 31th, 2020diagnosis, underlying disease, comorbidities to identify and analyze the profile of the patients included in the study.
Length of stay and inpatient settingsHospitalizations between April 8th to July 31th, 2020length of stay at Palliative Care unit (PC), ICU and PC & ICU to identify and analyze the profile of the patients included in the study and analyze the costs.

Contacts

Primary ContactMaria DC Otero Rodriguez, BSc
maria.rodriguez@hc.fm.usp.br+ 55 11 2661-2407
Backup ContactEdnalda M Franck, RN, MSc
ednalda.franck@hc.fm.usp.br+ 55 11 99814-6580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026